Cargando…

Risk prediction in medically treated chronic thromboembolic pulmonary hypertension

BACKGROUND: At present, there is no generally accepted comprehensive prognostic risk prediction model for medically treated chronic thromboembolic pulmonary hypertension (CTEPH) patients. METHODS: Consecutive medically treated CTEPH patients were enrolled in a national multicenter prospective regist...

Descripción completa

Detalles Bibliográficos
Autores principales: Quan, Ruilin, Yang, Yuanhua, Yang, Zhenwen, Tian, Hongyan, Li, Shengqing, Shen, Jieyan, Ji, Yingqun, Zhang, Gangcheng, Zhang, Caojin, Wang, Guangyi, Liu, Yuhao, Cheng, Zhaozhong, Yu, Zaixin, Song, Zhiyuan, Zheng, Zeqi, Cui, Wei, Chen, Yucheng, Liu, Shuang, Chen, Xiaoxi, Qian, Yuling, Xiong, Changming, Shan, Guangliang, He, Jianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056726/
https://www.ncbi.nlm.nih.gov/pubmed/33879094
http://dx.doi.org/10.1186/s12890-021-01495-6
_version_ 1783680707187441664
author Quan, Ruilin
Yang, Yuanhua
Yang, Zhenwen
Tian, Hongyan
Li, Shengqing
Shen, Jieyan
Ji, Yingqun
Zhang, Gangcheng
Zhang, Caojin
Wang, Guangyi
Liu, Yuhao
Cheng, Zhaozhong
Yu, Zaixin
Song, Zhiyuan
Zheng, Zeqi
Cui, Wei
Chen, Yucheng
Liu, Shuang
Chen, Xiaoxi
Qian, Yuling
Xiong, Changming
Shan, Guangliang
He, Jianguo
author_facet Quan, Ruilin
Yang, Yuanhua
Yang, Zhenwen
Tian, Hongyan
Li, Shengqing
Shen, Jieyan
Ji, Yingqun
Zhang, Gangcheng
Zhang, Caojin
Wang, Guangyi
Liu, Yuhao
Cheng, Zhaozhong
Yu, Zaixin
Song, Zhiyuan
Zheng, Zeqi
Cui, Wei
Chen, Yucheng
Liu, Shuang
Chen, Xiaoxi
Qian, Yuling
Xiong, Changming
Shan, Guangliang
He, Jianguo
author_sort Quan, Ruilin
collection PubMed
description BACKGROUND: At present, there is no generally accepted comprehensive prognostic risk prediction model for medically treated chronic thromboembolic pulmonary hypertension (CTEPH) patients. METHODS: Consecutive medically treated CTEPH patients were enrolled in a national multicenter prospective registry study from August 2009 to July 2018. A multivariable Cox proportional hazards model was utilized to derive the prognostic model, and a simplified risk score was created thereafter. Model performance was evaluated in terms of discrimination and calibration, and compared to the Swedish/COMPERA risk stratification method. Internal and external validation were conducted to validate the model performance. RESULTS: A total of 432 patients were enrolled. During a median follow-up time of 38.73 months (IQR: 20.79, 66.10), 94 patients (21.8%) died. The 1-, 3-, and 5-year survival estimates were 95.5%, 83.7%, and 70.9%, respectively. The final model included the following variables: the Swedish/COMPERA risk stratum (low-, intermediate- or high-risk stratum), pulmonary vascular resistance (PVR, ≤ or > 1600 dyn·s/cm(5)), total bilirubin (TBIL, ≤ or > 38 µmol/L) and chronic kidney disease (CKD, no or yes). Compared with the Swedish/COMPERA risk stratification method alone, both the derived model [C-index: 0.715; net reclassification improvement (NRI): 0.300; integrated discriminatory index (IDI): 0.095] and the risk score (C-index: 0.713; NRI: 0.300; IDI: 0.093) showed improved discriminatory power. The performance was validated in a validation cohort of 84 patients (C-index = 0.707 for the model and 0.721 for the risk score). CONCLUSIONS: A novel risk stratification strategy can serve as a useful tool for determining prognosis and guide management for medically treated CTEPH patients. Trial registration: ClinicalTrials.gov (Identifier: NCT01417338). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01495-6.
format Online
Article
Text
id pubmed-8056726
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80567262021-04-21 Risk prediction in medically treated chronic thromboembolic pulmonary hypertension Quan, Ruilin Yang, Yuanhua Yang, Zhenwen Tian, Hongyan Li, Shengqing Shen, Jieyan Ji, Yingqun Zhang, Gangcheng Zhang, Caojin Wang, Guangyi Liu, Yuhao Cheng, Zhaozhong Yu, Zaixin Song, Zhiyuan Zheng, Zeqi Cui, Wei Chen, Yucheng Liu, Shuang Chen, Xiaoxi Qian, Yuling Xiong, Changming Shan, Guangliang He, Jianguo BMC Pulm Med Research Article BACKGROUND: At present, there is no generally accepted comprehensive prognostic risk prediction model for medically treated chronic thromboembolic pulmonary hypertension (CTEPH) patients. METHODS: Consecutive medically treated CTEPH patients were enrolled in a national multicenter prospective registry study from August 2009 to July 2018. A multivariable Cox proportional hazards model was utilized to derive the prognostic model, and a simplified risk score was created thereafter. Model performance was evaluated in terms of discrimination and calibration, and compared to the Swedish/COMPERA risk stratification method. Internal and external validation were conducted to validate the model performance. RESULTS: A total of 432 patients were enrolled. During a median follow-up time of 38.73 months (IQR: 20.79, 66.10), 94 patients (21.8%) died. The 1-, 3-, and 5-year survival estimates were 95.5%, 83.7%, and 70.9%, respectively. The final model included the following variables: the Swedish/COMPERA risk stratum (low-, intermediate- or high-risk stratum), pulmonary vascular resistance (PVR, ≤ or > 1600 dyn·s/cm(5)), total bilirubin (TBIL, ≤ or > 38 µmol/L) and chronic kidney disease (CKD, no or yes). Compared with the Swedish/COMPERA risk stratification method alone, both the derived model [C-index: 0.715; net reclassification improvement (NRI): 0.300; integrated discriminatory index (IDI): 0.095] and the risk score (C-index: 0.713; NRI: 0.300; IDI: 0.093) showed improved discriminatory power. The performance was validated in a validation cohort of 84 patients (C-index = 0.707 for the model and 0.721 for the risk score). CONCLUSIONS: A novel risk stratification strategy can serve as a useful tool for determining prognosis and guide management for medically treated CTEPH patients. Trial registration: ClinicalTrials.gov (Identifier: NCT01417338). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01495-6. BioMed Central 2021-04-20 /pmc/articles/PMC8056726/ /pubmed/33879094 http://dx.doi.org/10.1186/s12890-021-01495-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Quan, Ruilin
Yang, Yuanhua
Yang, Zhenwen
Tian, Hongyan
Li, Shengqing
Shen, Jieyan
Ji, Yingqun
Zhang, Gangcheng
Zhang, Caojin
Wang, Guangyi
Liu, Yuhao
Cheng, Zhaozhong
Yu, Zaixin
Song, Zhiyuan
Zheng, Zeqi
Cui, Wei
Chen, Yucheng
Liu, Shuang
Chen, Xiaoxi
Qian, Yuling
Xiong, Changming
Shan, Guangliang
He, Jianguo
Risk prediction in medically treated chronic thromboembolic pulmonary hypertension
title Risk prediction in medically treated chronic thromboembolic pulmonary hypertension
title_full Risk prediction in medically treated chronic thromboembolic pulmonary hypertension
title_fullStr Risk prediction in medically treated chronic thromboembolic pulmonary hypertension
title_full_unstemmed Risk prediction in medically treated chronic thromboembolic pulmonary hypertension
title_short Risk prediction in medically treated chronic thromboembolic pulmonary hypertension
title_sort risk prediction in medically treated chronic thromboembolic pulmonary hypertension
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056726/
https://www.ncbi.nlm.nih.gov/pubmed/33879094
http://dx.doi.org/10.1186/s12890-021-01495-6
work_keys_str_mv AT quanruilin riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT yangyuanhua riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT yangzhenwen riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT tianhongyan riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT lishengqing riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT shenjieyan riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT jiyingqun riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT zhanggangcheng riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT zhangcaojin riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT wangguangyi riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT liuyuhao riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT chengzhaozhong riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT yuzaixin riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT songzhiyuan riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT zhengzeqi riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT cuiwei riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT chenyucheng riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT liushuang riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT chenxiaoxi riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT qianyuling riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT xiongchangming riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT shanguangliang riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension
AT hejianguo riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension